Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 28

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 28
---
;  

  interruption in global shipping affecting the transport of clinical trial materials, such as investigational drug product and comparator drugs used in our trials; and  

  employee furlough days that delay necessary interactions with local regulators, ethics committees and other important agencies and contractors.  

If we have difficulty enrolling sufficient numbers
of patients to conduct clinical trials as planned, we may need to delay or terminate clinical trials, either of which would have an adverse
effect on our business.

Use of our product candidates could be associated with side effects,
adverse events or other properties or safety risks, which could delay or halt their clinical development, prevent their regulatory approval,
cause us to suspend or discontinue clinical trials, abandon a product candidate, limit their commercial potential, if approved, or result
in other significant negative consequences that could severely harm our business, prospects, financial condition and results of operations.

As is the case with pharmaceuticals generally,
it is likely that there may be unexpected or undesirable side effects, but they can’t be disclosed since no clinical trials have
been conducted yet with this compound. Undesirable side effects may be found in the future. The side effects caused by these product candidates
could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the
delay or denial of regulatory approval by the FDA, the EMA or other comparable foreign regulatory authorities. The side effects related
to the product candidate could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential
product liability claims. Any of these occurrences may harm our business, financial condition, results of operations and prospects significantly.

Moreover, if our product candidates are associated
with undesirable side effects in preclinical studies or clinical trials or have characteristics that are unexpected, we may elect to abandon
their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics
are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the
product candidate if approved. We may also be required to modify or terminate our study plans based on findings in our preclinical studies
or clinical trials. Many product candidates that initially show promise in early-stage testing may later be found to cause side effects
that prevent further development. As we work to advance existing product candidates and to identify new product candidates, we cannot
be certain that later testing or trials of product candidates that initially showed promise in early testing will not be